There is a moment in almost every international case when the outcome and the cost are still open: the point of guarantee of payment, before treatment is committed. Traditional assistance tends to arrive after that moment has passed, reviewing the bill once the care has happened and the number is fixed. By then there is very little left to influence.
Pre-claim clinical intelligence moves the clinical conversation earlier, to the point where it can still change the case rather than just describe it.
Retrospective review audits. Pre-claim review shapes.
Auditing a bill after the fact catches errors and unbundles inflated charges. That is worth doing. But it is a rear-view mirror. The clinical decisions, the level of care, the length of stay and the pathway are all already set. The most a retrospective review can do is argue about what has already occurred.
Engaging at the guarantee-of-payment stage is different. A clinician can ask, before the event, whether the proposed treatment is medically necessary, whether the setting is right, and whether there is a more appropriate pathway, including bringing the patient home to a UK bed. Those questions change what happens next, not just what gets paid.
The window, and how fast it closes
It helps to think of an international case as a sequence of doors closing.
At first notification, everything is open. Nothing has been decided, no treatment has started, and the full range of pathways is available including doing something entirely different.
At guarantee of payment, most things are still open. The admission may not have happened. The operating list has not been booked. This is the point of maximum leverage, and it is the point traditional assistance most often misses, because a GOP request looks like an administrative task rather than a clinical one.
At admission, the setting is fixed and the length of stay is being determined by a treating team you are not talking to.
At discharge, the clinical decisions are all made. What remains is the bill.
At invoice, you are arguing about the price of things that have already happened.
The value of intervening is not linear across that sequence. It collapses.
What a guarantee of payment actually is
A GOP is usually treated as an access mechanism: the document that gets the member treated without paying upfront. That is half of what it is.
The other half is a control point. A guarantee issued with defined scope, meaning this indication, this proposed pathway, this admission, with any extension requiring a fresh decision, establishes what has been authorised before treatment proceeds. Issued open-ended, it is a blank cheque handed to a provider with every commercial reason to use it.
The difference costs nothing to implement. It is a matter of what the document says, and whether a clinician read the request before it went out.
It only works if clinicians are driving in real time
You cannot influence a treatment pathway you are only reviewing later. Pre-claim intelligence depends on clinicians who are in the case as it unfolds, with the authority to engage the treating team and the operational speed to do it within the window that matters. When a case is escalated, minutes decide both cost and outcome, and a defined clinical escalation ladder is what turns intent into action.
The objection: you are second-guessing the treating physician
The challenge is fair, and worth answering directly rather than around.
A clinician reviewing a case at distance has less information than the doctor standing at the bedside. That is true, and it should make the reviewing clinician humble about the things that genuinely require examination. It does not make them unqualified to ask whether an admission for observation is indicated, whether an MRI repeats a CT taken four days ago at another facility, or whether the proposed length of stay matches the presentation.
There is also a fact about incentives that is uncomfortable but real. A treating physician in a private facility that bills an insurer is not neutral about volume. Neither, in the other direction, is a cost containment provider. The way to resolve competing incentives is not to pretend they do not exist. It is to make the reasoning explicit, put it in writing, attach a name to it, and let it be reviewed.
Where the treating team’s answer is good, the challenge stops there. That happens often, and it should. A challenge process that never concedes is not a clinical process.
What it needs to work
Pre-claim intelligence fails in practice for reasons that are almost never clinical:
- Speed. If the clinical review takes two days, the surgery has happened. The window is measured in hours, which is why our clinical escalations carry a fifteen-minute commitment rather than a target.
- Reach. A clinician who cannot get the treating physician on the phone cannot influence anything. Access is an operational capability, not a clinical one.
- Information. Deciding on a two-line GOP request is guessing. Getting the clinical detail before deciding is most of the work.
- Standing. If the clinician can advise but the authorisation goes out regardless, the review is theatre.
Evidenced, not improvised
Intervening early raises the stakes on defensibility. Every pre-claim decision has to be clinically grounded and recorded, so that the reasoning stands up to the insurer, the regulator and, if it comes to it, the courts. Captured as it happens through Atlas, that record is an asset rather than a reconstruction.
The shift from reactive to pre-claim is not a slogan. It is the difference between managing a case and inheriting one.
For where this sits against the other levers on a loss ratio, see medical inflation and the IPMI loss ratio, and for the mechanics in practice, medical cost containment.
